Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Advances in Pharmacomicrobiomics
share announcement

Advances in Pharmacomicrobiomics

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 3531

Special Issue Editor

Dr. Mauro Cataldi

E-Mail Website
Guest Editor
Division of Pharmacology, Federico II University of Naples, Naples, Italy
Interests: geriatric pharmacology; precision medicine; therapy optimization; pharmacomicrobiomics; pharmanutrition
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Precision medicine aims to identify which drugs at which doses represent the best therapy for every single patient. Indeed, clinical responses to drug therapy are known to be highly variable interindividually. Furthermore, classically, genetic and environmental factors have been identified as major determinants of this variability; nowadays, there is great excitement for new data that suggest that microbiota also have a role. Evidence is being accumulated that commensal microorganisms living in the human body may metabolize and/or accumulate intracellular drugs given to treat specific diseases, and, therefore, they may affect their clinical efficacy. In addition, these microorganisms may affect drug responses by interfering with drug pharmacodynamics. All of these effects may change interindividually and contribute to the variability in drug responses, since the composition of human microbiota may differ in different individuals and be modified by disease status. The term pharmacomicrobiomics has been introduced to describe the contribution of microbiota to the variability in drug pharmacokinetics and pharmacodynamics. This Special Issue is intended to provide an updated overview on the recent progress in the field of pharmacomicrobiomics, also including strategies to modify the composition of microbiota to improve drug responses. Both original studies and review articles are welcomed for this Special Issue, which we hope will represent a stimulating forum for this new field of precision medicine.

Dr. Mauro Cataldi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • pharmacomicrobiomics
  • microbiota
  • pharmacokinetics
  • pharmacodynamics
  • bioavailability

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

16 pages, 610 KiB  
Review
Role of the Intestinal Microbiota in the Genesis of Major Depression and the Response to Antidepressant Drug Therapy: A Narrative Review
by Tiziana Mundula, Simone Baldi, Elisabetta Gerace and Amedeo Amedei
Biomedicines 2023, 11(2), 550; https://doi.org/10.3390/biomedicines11020550 - 14 Feb 2023
Cited by 1 | Viewed by 2068
Abstract
A major depressive disorder is a serious mental illness characterized by a pervasive low mood that negatively concerns personal life, work life, or education, affecting millions of people worldwide. To date, due to the complexity of the disease, the most common and effective [...] Read more.
A major depressive disorder is a serious mental illness characterized by a pervasive low mood that negatively concerns personal life, work life, or education, affecting millions of people worldwide. To date, due to the complexity of the disease, the most common and effective treatments consist of a multi-therapy approach, including psychological, social, and pharmacological support with antidepressant drugs. In general, antidepressants are effective in correcting chemical imbalances of neurotransmitters in the brain, but recent evidence has underlined the pivotal role of gut microbiota (GM) also in the regulation of their pharmacokinetics/pharmacodynamics, through indirect or direct mechanisms. The study of these complex interactions between GM and drugs is currently under the spotlight, and it has been recently named “pharmacomicrobiomics”. Hence, the purpose of this review is to summarize the contribution of GM and its metabolites in depression, as well as their role in the metabolism and activity of antidepressant drugs, in order to pave the way for the personalized administration of antidepressant therapies. Full article
(This article belongs to the Special Issue Advances in Pharmacomicrobiomics)
►▼ Show Figures

Figure 1

Other

Jump to: Review

32 pages, 2551 KiB  
Systematic Review
Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review
by Annalaura Manes, Tiziana Di Renzo, Loreta Dodani, Anna Reale, Claudia Gautiero, Mariastella Di Lauro, Gilda Nasti, Federica Manco, Espedita Muscariello, Bruna Guida, Giovanni Tarantino and Mauro Cataldi
Biomedicines 2023, 11(9), 2562; https://doi.org/10.3390/biomedicines11092562 - 18 Sep 2023
Cited by 3 | Viewed by 1080
Abstract
The clinical response to classical immunosuppressant drugs (cIMDs) is highly variable among individuals. We performed a systematic review of published evidence supporting the hypothesis that gut microorganisms may contribute to this variability by affecting cIMD pharmacokinetics, efficacy or tolerability. The evidence that these [...] Read more.
The clinical response to classical immunosuppressant drugs (cIMDs) is highly variable among individuals. We performed a systematic review of published evidence supporting the hypothesis that gut microorganisms may contribute to this variability by affecting cIMD pharmacokinetics, efficacy or tolerability. The evidence that these drugs affect the composition of intestinal microbiota was also reviewed. The PubMed and Scopus databases were searched using specific keywords without limits of species (human or animal) or time from publication. One thousand and fifty five published papers were retrieved in the initial database search. After screening, 50 papers were selected to be reviewed. Potential effects on cIMD pharmacokinetics, efficacy or tolerability were observed in 17/20 papers evaluating this issue, in particular with tacrolimus, cyclosporine, mycophenolic acid and corticosteroids, whereas evidence was missing for everolimus and sirolimus. Only one of the papers investigating the effect of cIMDs on the gut microbiota reported negative results while all the others showed significant changes in the relative abundance of specific intestinal bacteria. However, no unique pattern of microbiota modification was observed across the different studies. In conclusion, the available evidence supports the hypothesis that intestinal microbiota could contribute to the variability in the response to some cIMDs, whereas data are still missing for others. Full article
(This article belongs to the Special Issue Advances in Pharmacomicrobiomics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop